641. AN OVERVIEW OF THE PROJECT EXPLORING GENE-DRUG PAIRS IN DOSE GUIDANCE OF ANTIDEPRESSANTS AND ANTIPSYCHOTICS

Abstract Background Pharmacological treatment is one of the key components in the treatment of mental disorders. Unfortunately, only one-third of patients adequately responds to the initial treatment and adverse effects are very common. Genetic heterogeneity of patients is one of the reasons for the high variability in response and for adverse effects. Pharmacogenetic testing of genes encoding drug-metabolizing enzymes could guide physicians to choose the most appropriate medication and facilitate the dosing process. Aims & Objectives The PSY-PGx Consortium, funded by the European Union’s Horizon 2020 Program (EUR ~8 million, 60-month duration, Grant Agreement ID: 945151), aims to provide further evidence to this end, both by conducting a multi-center non-industry sponsored clinical study and by interrogating available large-scale biobank data. Method The European Union-funded and researcher-initiated PSY-PGx project was launched in 2021 (https://cordis.europa.eu/project/id/945151). It is the largest non-industry-funded project to implement pharmacogenetics in clinical psychiatry. As part of this project the UK population-based biobank UKB (https://www.ukbiobank.ac.uk), was assessed for the relationship between pharmacogenomics and clinical outcomes in patients with psychiatric disorders6. A medication prescription algorithm will be derived from these data. Results Even amongst countries that are governed by the same overarching EU regulations, requirements for ethical approval differ considerably regarding the clinical study. At the time of submission, over 150 patients from four clinical centers were either enrolled in or had already completed the PSY-PGx clinical study. Data will be presented from 11437 mood disorder patients who present medication data from primary care sources. Medication success is defined as >12 weeks continuous antidepressant intake and failure as <6 weeks intake. Discussion & Conclusions Further progress and challenges of this international project will be presented at the meeting. The ultimate goal of this research is to develop an algorithm that can predict the most effective medication for individual patients, not just based on their phenotype, but by incorporating a wide range of factors. By identifying the complex interactions between these factors and treatment outcomes, this study seeks to contribute to the field of personalized psychiatric care, offering insights into more tailored and effective treatment strategies for psychiatric disorders.